Mecinaj, A
Gulati, G
Heck, SL
Holte, E
Fagerland, MW
Larsen, AI
Blix, E.S
Geisler, J
Wethal, T
Omland, T
Funding for this research was provided by:
Kreftforeningen (198136)
Helse Sør-Øst RHF (2019087)
Program for klinisk behandlingsforskning, Helse Sør-Øst
Article History
Received: 15 March 2021
Accepted: 16 July 2021
First Online: 27 September 2021
Declarations
:
: The study protocol, including the patient information and informed consent form, has been approved by Regional Ethics Committee (ref. nr. 2017/2411–1) and The Norwegian Medicines Agency.
: Not applicable.
: GG has received speaker honoraria from Novartis, AstraZeneca and Bristol-Myers Squibb. TO has served on advisory boards for Abbott Diagnostics, Roche Diagnostics and Bayer and has received research support from Abbott Diagnostics, Novartis, Roche Diagnostics, Singulex and SomaLogic via Akershus University Hospital, and speaker’s or consulting honoraria from Roche Diagnostics, Siemens Healthineers and CardiNor. ESB has received speaker honoraria from Roche.